Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jun;27 Suppl 1(Suppl 1):S7-13.
doi: 10.1007/s12032-010-9527-y. Epub 2010 Apr 20.

Mechanism of action of immunomodulatory agents in multiple myeloma

Thomas Reske  1 , Mariateresa Fulciniti, Nikhil C Munshi
Affiliations
Review

Mechanism of action of immunomodulatory agents in multiple myeloma

Thomas Reske et al. Med Oncol. 2010 Jun.

Abstract

Immunomodulatory agents (IMiD's) have become an important drug category in the treatment of multiple myeloma. The agents have a complex mechanism of action that influence the microenvironment in the bone marrow. The microenvironment is an essential promotor of disease progression and therefore important in targeting the disease. The article reviews mechanism of action and essential pathways of IMiD's that are important in disease treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statements Thomas Reske: No conflicts to report. Mariateresa Fulciniti and Nikhil C. Munshi: Advisory board/ Consultant for Celgene Corporation, Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation.

Figures

Fig. 1
Fig. 1
IMiD mechanism of action—IMiDs Target MM cells in its microenvironment
Fig. 2
Fig. 2
Activation of caspase pathways by IMiDs and other agents active in myeloma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anderson KC. Lenalidomide and thalidomide: mechanisms of action—similarities and differences. Semin Hematol. 2005;42:S3–8. - PubMed
    1. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525–30. - PubMed
    1. Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res. 2006;30:849–58. - PubMed
    1. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943–50. - PubMed
    1. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997;11:27–42. - PubMed

Publication types

MeSH terms